Receptor Tyrosine Protein Kinase ERBB3 Market to Emerge at a Rapid Pace during the Forecast Period

Introduction

Targeted therapy has revolutionized the treatment landscape of various types of cancer. Currently, HER3 based drugs are not available in the market or have not received any approval from the FDA. However, several American and European players are continuously working to seek approval for HER3 based drugs, and they are heavily investing in advanced technology and R&D activities for product innovation and development. The HER3-based drugs are expected to enter the market by 2025, which is likely to revolutionize cancer treatment across Europe and America.

PIPELINE PRODUCTS

In the last few years, the global market has witnessed significant growth in the prevalence of various types of cancer across the globe. To address the dire situation, numerous players are constantly working on drug development and FDA approval. Currently, several HER3 drugs are in the pipeline and waiting for FDA approval. The study suggests that only HER3 acting drugs may not be that effective, but a combination with any chemotherapy drug can become a prominent option to treat cancers. Apart from this, many players are putting efforts into developing monoclonal antibodies against HER3.

We believe that rapidly growing drug resistance is one of the prime factors for drug failure as it limits the efficacy of many targeted therapies, including mono-/bispecific antibodies and small-molecule inhibitors. As per the clinical studies and findings, it is suggested that concomitant suppression of HER3 with other receptor tyrosine kinases (RTKs), such as EGFR family members, may appear to be helpful in attaining better clinical benefits. Moreover, the combination of HER-2 and HER-3 can offer a promising opportunity for treating colorectal cancer in the years to come.

Key Highlights

• The Elgemtumab segment is expected to dominate the market
• North America’sreceptor tyrosine-protein kinase ERBB 3 market is expected to dominate during the forecast period, owing to the presence of key firms that are actively investing in umpteen clinical trials and research activities to seek approval for HER3 for treating cancer

Competitive Players

1. AstraZeneca Plc (UK)
2. AVEO Pharmaceuticals, Inc. (US)
3. Etubics Corporation (South Korea)
4. F. Hoffmann-La Roche Ltd. (Switzerland)
5. GamaMabs Pharma S.A. (France)
6. Merck KGaA (Germany)
7. Pfizer Inc. (US)
8. Novartis International AG (Switzerland)
9. Bayer AG (Germany)
10. BeiGene, Ltd. (China)
11. Seagen Inc. (US)
12. Exelixis, Inc. (US)
13. Mirati Therapeutics, Inc. (US)
14. Pyxis Oncology, Inc. (US)
15. Herceptin Biosimilar Manufacturers

Recent Developments

• March 2024- Daiichi Sankyo Company, a global pharmaceutical company, announced positive results from a Phase 3 clinical trial evaluating its ERBB 3-targeted antibody-drug conjugate (ADC), patritumab deruxtecan (U3-1402), for the treatment of metastatic non-small cell lung cancer (NSCLC).
• October 2023- AstraZeneca, a leading biopharmaceutical company, announced the initiation of a global Phase 2/3 clinical trial for its ERBB 3-targeted monoclonal antibody, seribantumab, in combination with its antibody-drug conjugate, trastuzumab deruxtecan (Enhertu), for the treatment of metastatic breast cancer.

Segmentation

1. By Type
   1. Polyclonal Antibody
   2. Monoclonal Antibody
2. By Applications
   1. ELISA
   2. Immunoprecipitation
   3. Immunofluorescence
   4. Western Blot
   5. Flow Cytometry
   6. Other